替妥木单抗所致耳科不良事件的前瞻性评估:初步结果
前瞻性队列研究纳入2020年5月至2022年1月接受替妥木单抗治疗的35例成人患者,采用常规及超高频听力计、鼓室压图、言语识别率和畸变产物耳声发射检测。最常见主观症状为听力下降(25.7%)。14例有治疗前后听力数据的患者中,3例(21.4%)常规频率听力变化,10例(71.4%)高频听力变化。3例(8.6%)确诊为咽鼓管异常开放。
要点
- 替妥木单抗治疗者耳科症状发生率高,最常见为听力下降(25.7%)。
- 有治疗前后听力数据的14例中,常规频率听力变化3/14(21.4%),高频听力变化10/14(71.4%)。
- 11例纯音听力变化者中不足半数(n=5)主诉听力下降;2例因听力下降停药。
核心结论
- 本队列中替妥木单抗使用与高发的耳科症状相关,主观听力下降、超高频听力变化及咽鼓管功能障碍均可见,提示替妥木单抗潜在耳毒性。
研究设计与样本
- 前瞻性队列研究,纳入2020年5月至2022年1月接受替妥木单抗治疗的成人患者,来自三级转诊中心。
主要发现
- 共招募35例患者,中位(范围)年龄48.5岁(21-74),男性8例(22.8%)。
- 最常见主观症状为听力下降(25.7%),其次为耳闷胀感(17.1%)和耳鸣(14.3%)。
- 14例有治疗前后听力数据:3例(21.4%)常规频率听力变化,10例(71.4%)高频听力变化,2例两者均有。
- 11例常规或高频纯音听力变化者中,仅5例主诉听力下降;13例中4例(30.7%)畸变产物耳声发射变化。
- 2例因听力下降停药;3例(8.6%)经耳鼻咽喉科医生诊断为咽鼓管异常开放(PET),另3例据眼科随访中症状描述疑为PET。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess a series of patients receiving teprotumumab therapy and objectively quantify the rates of otologic adverse events. STUDY DESIGN: A prospective cohort study of adult patients receiving teprotumumab between May 2020 and January 2022. SETTING: Tertiary referral center. METHODS: Prior to treatment initiation, an ototoxicity-specific audiometric battery was completed, which included conventional audiometry (frequencies 250-8000 Hz), ultrahigh-frequency audiometry (9000-20,000 Hz), tympanometry, speech discrimination scores, and distortion product otoacoustic emissions (DPOAEs). Testing was then repeated after treatment completion. RESULTS: In total, 35 patients were recruited, with a median (range) age of 48.5 years (21-74), and 8 (22.8%) were male. The most common subjective symptom reported was a hearing decline (25.7%), followed by aural fullness (17.1%) and tinnitus (14.3%). Fourteen patients had both pre- and posttreatment audiometric data. Among them, 3 patients (21.4%) were found to have changes in standard frequency audiometry, and 10 (71.4%) had changes in high-frequency audiometry, with 2 patients having changes in both. Less than half (n = 5) of the 11 patients with changes in standard or high-frequency pure tone hearing noted subjective hearing decline. Changes in DPOAE were noted in 4 patients out of 13 (30.7%). Two patients discontinued treatment due to hearing decline. Finally, 3 patients (8.6%) were diagnosed with patulous eustachian tube (PET) by an otolaryngologist, and another 3 patients are suspected to have PET based on symptom description during ophthalmologic follow-up. CONCLUSION: In our cohort, a high incidence of otologic symptoms was found to be associated with teprotumumab usage. Subjective hearing decline, changes in ultrahigh-frequency hearing as well as eustachian tube dysfunction may be encountered and suggest the potential ototoxicity of teprotumumab.
引用
- Kay-Rivest E, Belinsky I, Kozlova A, et al. Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results. Otolaryngol Head Neck Surg. 2023. PMID: 36939482. doi:10.1002/ohn.174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。